Question for the group. We have a recommendation from DSMC that we measure efficacy at 42 days. When we review the results either after 293 or 390 enrollees, we can review at 28 days. At the same time, with either review, probably 80% of the patients would have 42 days since first being injected. So why not construct results data that show primary end point efficacy of the whole group, but also provide the results for those who have been on the drug for 42 days. Certainly the calculations could be done.